Larotinib (mesylate hydrate)

Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1].

Product Specifications

CAS Number

[2097129-93-4]

UNSPSC

12352005

Target

Btk; EGFR; IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/larotinib-mesylate-hydrate.html

Concentration

10mM

Purity

98.66

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

COC(C(OCCCN1C[C@]2([H])[C@](OCCO2)([H])C1)=C3)=CC4=C3C(NC5=CC(Cl)=C(C=C5)F)=NC=N4.CS(=O)(O)=O.CS(=O)(O)=O.O

Molecular Formula

C26H36ClFN4O11S2

Molecular Weight

699.17

References & Citations

[1]Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.